Frontiers in Medicine (Apr 2021)
Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations
- Zeynep Talip,
- Francesca Borgna,
- Cristina Müller,
- Cristina Müller,
- Jiri Ulrich,
- Charlotte Duchemin,
- Charlotte Duchemin,
- Joao P. Ramos,
- Joao P. Ramos,
- Thierry Stora,
- Ulli Köster,
- Youcef Nedjadi,
- Vadim Gadelshin,
- Vadim Gadelshin,
- Vadim Gadelshin,
- Valentin N. Fedosseev,
- Frederic Juget,
- Claude Bailat,
- Adelheid Fankhauser,
- Shane G. Wilkins,
- Laura Lambert,
- Bruce Marsh,
- Dmitry Fedorov,
- Eric Chevallay,
- Pascal Fernier,
- Roger Schibli,
- Roger Schibli,
- Nicholas P. van der Meulen,
- Nicholas P. van der Meulen
Affiliations
- Zeynep Talip
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
- Francesca Borgna
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
- Cristina Müller
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
- Cristina Müller
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
- Jiri Ulrich
- Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, Switzerland
- Charlotte Duchemin
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Charlotte Duchemin
- Institute for Nuclear and Radiation Physics, Catholic University of Leuven, Leuven, Belgium
- Joao P. Ramos
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Joao P. Ramos
- Institute for Nuclear and Radiation Physics, Catholic University of Leuven, Leuven, Belgium
- Thierry Stora
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Ulli Köster
- Institut Laue-Langevin, Grenoble, France
- Youcef Nedjadi
- Institute of Radiation Physics, University Hospital and University of Lausanne, Lausanne, Switzerland
- Vadim Gadelshin
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Vadim Gadelshin
- Institute of Physics, Johannes Gutenberg University, Mainz, Germany
- Vadim Gadelshin
- Institute of Physics and Technology, Ural Federal University, Yekaterinburg, Russia
- Valentin N. Fedosseev
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Frederic Juget
- Institute of Radiation Physics, University Hospital and University of Lausanne, Lausanne, Switzerland
- Claude Bailat
- Institute of Radiation Physics, University Hospital and University of Lausanne, Lausanne, Switzerland
- Adelheid Fankhauser
- 0Analytic Radioactive Materials, Paul Scherrer Institute, Villigen, Switzerland
- Shane G. Wilkins
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Laura Lambert
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Bruce Marsh
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Dmitry Fedorov
- 1Petersburg Nuclear Physics Institute, National Research Center Kurchatov Institute, Gatchina, Russia
- Eric Chevallay
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Pascal Fernier
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Roger Schibli
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
- Roger Schibli
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
- Nicholas P. van der Meulen
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
- Nicholas P. van der Meulen
- Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, Switzerland
- DOI
- https://doi.org/10.3389/fmed.2021.643175
- Journal volume & issue
-
Vol. 8
Abstract
The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.
Keywords
- Er-169
- electromagnetic isotope separation
- lanthanide-separation
- activity standardization
- in vitro studies
- laser resonance ionization